157 related articles for article (PubMed ID: 30114867)
41. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
Simms KT; Smith MA; Lew JB; Kitchener HC; Castle PE; Canfell K
Int J Cancer; 2016 Dec; 139(12):2771-2780. PubMed ID: 27541596
[TBL] [Abstract][Full Text] [Related]
42. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
43. HPV single-dose vaccination: Impact potential, evidence base and further evaluation.
Stanley M; Dull P
Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700
[No Abstract] [Full Text] [Related]
44. Options for design of real-world impact studies of single-dose vaccine schedules.
Franceschi S; Clifford GM; Baussano I
Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
[TBL] [Abstract][Full Text] [Related]
45. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
46. What can surveillance of genital warts tell us?
Fairley CK; Donovan B
Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
[TBL] [Abstract][Full Text] [Related]
47. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Flaherty DK; Alkhateeb FM
Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
[TBL] [Abstract][Full Text] [Related]
48. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
Gilca V; Salmerón-Castro J; Sauvageau C; Ogilvie G; Landry M; Naus M; Lazcano-Ponce E
Vaccine; 2018 Aug; 36(32 Pt A):4800-4805. PubMed ID: 29887322
[TBL] [Abstract][Full Text] [Related]
49. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
50. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.
Sankaranarayanan R
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 1():S33-5. PubMed ID: 26433502
[TBL] [Abstract][Full Text] [Related]
51. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
[TBL] [Abstract][Full Text] [Related]
52. Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.
Perkins RB; Lin M; Wallington SF; Hanchate A
Sex Transm Dis; 2017 Jun; 44(6):365-370. PubMed ID: 28499288
[TBL] [Abstract][Full Text] [Related]
53. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
54. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
55. Safety of HPV vaccines in the age of nonavalent vaccination.
Quattrone F; Canale A; Filippetti E; Tulipani A; Porretta A; Lopalco PL
Minerva Pediatr; 2018 Feb; 70(1):59-66. PubMed ID: 29363293
[TBL] [Abstract][Full Text] [Related]
56. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India.
Bhatla N; Meena J; Gupta K; Pal B; Divakar H; Bhalerao S; Peedicayil A; Srivastava S; Basu P; Purandare CN;
J Obstet Gynaecol Res; 2020 Sep; 46(9):1651-1660. PubMed ID: 32627278
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
Haupt RM; Sings HL
J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
